Celgene Corporation (NASDAQ: CELG) delivered a net product sales rise of 17% yoy to $3,479 million in FY17 while the fourth quarter of 2017 total revenue reached $3,483 million.

All three key product segments- REVLIMID, POMALYST®/IMNOVID and OTEZLA delivered a decent performance in the fourth quarter of 2017 leading to a better top line.

REVLIMID® sales rose 21% to $2,188 million in the fourth quarter of 2017 with U.S. sales rising 24% to $1,473 million and international sales increasing 15% yoy to $715 million. REVLIMID® sales rose 17% yoy to $8,187 million, in FY17 driven by rise in duration and market share.

POMALYST®/IMNOVID® sales enhanced 17% yoy to $442 million in 4Q17 with U.S. sales rose 29% to $283 million and international sales remained at $159 million. POMALYST®/IMNOVID® sales for FY17 rose 23% yoy to $1,614 million. OTEZLA® sales enhanced 22% yoy to 371 million in 4Q17 with U.S. sales rising 13% yoy to $303 million and international sales surging 84% yoy to $68 million. OTEZLA® sales surged 26% yoy to $1,279 million, for FY17 .

Other major update worth to note are that the group made agreement to acquire Impact Biomedicines, Inc., in 2018 which is a privately-held biotechnology firm developing fedratinib, a highly selective JAK2 kinase inhibitor, for myelofibrosis and polycythemia vera. The group paid over $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. This acquisition would expand strategic development options within Celgene’s myeloid portfolio of assets. The group is also acquiring Juno Therapeutics, Inc., which is focused on developing innovative cellular immunotherapies for the treatment of cancer. They would pay $87 per share in cash, or a total of over $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares). With these moves, the group would strengthen their leadership in hematology and oncology as well as advance Celgene’s global leadership in cellular immunotherapy.

The shares of CELG lost over 12.7% in the last three months but rose over 1.2% on Jan 25^th, 2018 (as of 11:27AM EST; Source: Google finance).